| Today’s Big NewsSep 7, 2023 |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today. 
|
|
| By Angus Liu Roche may not receive the FDA's decision on a subcutaneous version of its cancer immunotherapy Tecentriq on time thanks to the agency's requirement for changes to the drug's manufacturing process. |
|
|
|
| Philadelphia, PA |  |
|
|
By Andrea Park The first settlement covers only economic loss claims. Hundreds of personal injury and wrongful death claims still have yet to be tied off. |
By Kevin Dunleavy Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies. |
By James Waldron Roche’s $310 million splash into the metabolic therapy pool two months ago already appears to be paying off, with its Alnylam-partnered hypertension med reducing blood pressure in a phase 2 trial. |
|
Thursday, September 14, 2023 | 11am ET / 8am PT Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. Join industry experts to learn about innovative strategies being used to unlock challenging targets. Register now. 
|
|
By Andrea Park In less than a month, Zimmer Biomet’s executive team has gotten quite the makeover. |
By James Waldron What do you get when you combine the established cancer modality of antibody-drug conjugation with targeted protein degradation? An intriguing new class of antibody drugs called degrader-antibody conjugates—and Seagen is keen to get in on the ground floor. |
By Conor Hale Compared to its predecessor, the Watchman FLX Pro features a new polymer coating designed to assist in the natural healing process following the procedure. |
By Gabrielle Masson Investors have reached deep into their pocketbooks for Mariana Oncology’s series B financing, with Eli Lilly coming aboard for the oversubscribed $175 million round aimed at making waves in radiopharmaceutical development. |
By Helen Floersh Novo Nordisk will collaborate with Harvard and the Broad Institute of Massachusetts Institute of Technology to develop three new programs over the next three years to tackle diabetes and cardiac fibrosis. |
By Fraiser Kansteiner Engineering construction workers—who help repair and maintain pharmaceutical plants, oil refineries and more—are weighing whether to strike in the United Kingdom. The potential industrial action, centered on a pay dispute, could affect two GSK sites. But it's still too early to say whether the contractors will actually strike. |
|
Thursday, September 21, 2023 | 2pm ET / 11am PT In today's ever-evolving healthcare landscape, understanding and leveraging data to develop comprehensive insights is crucial to stay ahead. Specialty datasets, such as genomics, clinical, labs, and patient hub data, are critical to unlock deeper insights and improve healthcare data utilization, and it’s important to ensure these various sources of data seamlessly integrate. Register now to learn more. 
|
|
Whitepaper Access this insightful whitepaper to explore the role collaboration platform technology can play in helping address current industry challenges and to generate business value. Sponsored by: Zoom |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
